Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

PURPOSE: Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the adverse effect of PPIs on patients with non-small cell lung cancer (NSCLC) treated with first-line EGFR TKIs remains c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yu-Hung, Yang, Yao-Hsu, Hsieh, Meng-Jer, Hung, Ming-Szu, Lin, Yu-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756852/
https://www.ncbi.nlm.nih.gov/pubmed/31572008
http://dx.doi.org/10.2147/CMAR.S222278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756852/
https://www.ncbi.nlm.nih.gov/pubmed/31572008
http://dx.doi.org/10.2147/CMAR.S222278

Ejemplares similares